The primary audience for the guideline is health programme managers, including governmental and non-governmental organizations, and policy makers who are responsible for designing maternal, newborn and child health programmes, primarily in low-income settings. The guideline is also aimed at health p...roviders and teaching institutions, to increase knowledge of interventions. Development programmes and organizations supporting women’s empowerment and rights will also find this guideline of use.
more
Integration of mental health (MH) and HIV programs has the potential to significantly improve health outcomes for people living with HIV (PLHIV). This training package, which is comprised of a training-of-trainers manual, an accompanying presentation, and a standard operating procedure, was develope...d to support a pilot project for MH and HIV integration at the community level such that
health facilities, community-based organizations (CBOs), and traditional medical practitioners (TMPs) can collaborate to support MH screening and service provision for PLHIV in Zimbabwe
more
The strategy focuses on mobilizing and coordinating partners, experts and resources to help countries enhance surveillance of the Zika virus and disorders that could be linked to it, improve vector control, effectively communicate risks, guidance and protection measures, provide medical care to thos...e affected and fast-track research and development of vaccines, diagnostics and therapeutics
more
Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance on the methodology to be used for assessing, at field level, the yellow fever virus circulation in areas at risk, and is primarily intended fo...r public health specialists
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
BMC Health Services Research BMC series – open, inclusive and trusted201818:251; https://doi.org/10.1186/s12913-018-3072-3